PROFESSIONAL EDITION

The largest community of pharma leaders

TrialScope Supports Moderna for Diversity Enrollment in Moderna’s Phase 3 Study of its COVID-19 Vaccine

JERSEY CITY, N.J.–(BUSINESS WIRE)–Fulfilling a commitment to diversity and inclusion in the Phase 3 COVE Study of the Moderna COVID-19 Vaccine, Moderna enlisted the help of TrialScope, the global leader in clinical trial disclosure and transparency technology, for patient recruitment. Moderna utilized TrialScope Connect, an industry-first patient referral collective that connects sponsors and clinical trial recruitment partners to rapidly find, screen and enroll clinical trial participants.

In October 2020, Moderna completed recruitment of more than 30,000 participants in the Phase 3 study of its COVID-19 Vaccine, utilizing TrialScope Connect’s platform in the final enrollment period to ensure inclusion of participants from communities that have historically been underrepresented in clinical research and are disproportionately impacted by COVID-19. The study included more than 11,000 participants from communities of color, reflecting U.S. demographics.

Unlike traditional clinical trial recruitment models, TrialScope Connect works as a collective, empowering over 75 different recruitment partners to refer patients to research sites simultaneously using a pay-for-performance model. The platform provided Moderna with real-time site performance metrics to streamline recruitment, flagging overwhelmed sites and quickly rerouting new referrals to ease congestion. With clinical research sites often juggling multiple trials, easing the burden of unqualified referrals early on is a key priority. Rather than allowing COVE Study website visitors to contact sites independently, TrialScope Connect’s embedded prescreening solution quickly prequalified leads, preventing more than 10,000 unqualified referrals from contacting already busy sites.​ ​

TrialScope Connect partners that contributed to enrollment in Moderna’s Phase 3 trial include:

“I am proud that Moderna was open to using a novel approach to clinical trial recruitment for the COVE Study,” said Melanie Ivarsson, Ph.D., Chief Development Officer at Moderna. “We were committed to ensuring that the COVE study included a diverse population including those who have been historically underrepresented in clinical research and have been disproportionately impacted by COVID-19. With TrialScope Connect, dozens of recruitment partners answered the call at once, which helped us meet our milestones.”

“When we set out to build TrialScope Connect, we knew that the old way of recruiting for clinical trials wasn’t working, but we never knew our referral network would be instrumental in supporting enrollment in this important clinical trial,” said TrialScope CEO Jeff Kozloff. “While the coronavirus pandemic has proved a monumental challenge for people across the globe, Moderna is at the forefront of the fight, and we are thrilled to play a small but important supporting role.”

About TrialScope

TrialScope gives your clinical trial data superpowers™. The TrialScope Transparency Cloud™ makes centralizing, structuring and activating clinical trial information simple, for use across the organization and at every stage of the study. Our integrated platform is used by 16 of the top 20 clinical trial sponsors in the world, who rely on TrialScope to ensure disclosure compliance, maximize trial transparency, improve patient engagement and accelerate study recruitment. To learn more, visit TrialScope.com.

TrialScope was acquired by Informa Pharma Intelligence in 2020, combining its powerful technology for disclosure, transparency and recruitment with leading brands, data and solutions for the clinical trials and broader pharmaceutical and biomedical industry.

About Informa Pharma Intelligence

Informa Pharma Intelligence powers a full suite of analysis products—Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Medtrack™, Biomedtracker™, Scrip™, Pink Sheet™ In Vivo™ and most recently TrialScope—to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth. With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.

Contacts

Darcy Grabenstein
darcy@trialscope.com
+1 929-278-5784

Source Read More

Recent Articles